Novel genetic loci associated with hippocampal
暂无分享,去创建一个
Kai-Uwe Eckardt | K. Eckardt | F. Carrera | Yvonne Meier | S. Roger | C. Gaillard | A. Bock | S. Larroque | Yvonne Meier | Andreas H. Bock | Fernando Carrera | Carlo Gaillard | David Van Wyck | Sylvain Larroque | Simon D. Roger | D. Wyck
[1] J. Kusek,et al. A randomized trial of intravenous and oral iron in chronic kidney disease , 2015, Kidney international.
[2] B. Jaber. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. , 2008, Kidney international.
[3] F. Dominici,et al. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model , 2014, Drug Research.
[4] G. Bailie,et al. Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis , 2005, Nephron Clinical Practice.
[5] D. Bregman,et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] D. Leehey,et al. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[8] I. Macdougall,et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] R. Agarwal,et al. Acute injury with intravenous iron and concerns regarding long-term safety. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[10] Shixiang Wang,et al. Intravenous Iron Sucrose in Chinese Hemodialysis Patients with Renal Anemia , 2008, Blood Purification.
[11] I. Macdougall,et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. , 1996, Kidney international.
[12] G. Jong,et al. ‘Oversaturation’ of transferrin after intravenous ferric gluconate (FerrlecitR) in haemodialysis patients , 1996 .
[13] Shawn D. Chase,et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. , 2004, Kidney international.
[14] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[15] M. Brookhart,et al. Changing patterns of anemia management in US hemodialysis patients. , 2012, The American journal of medicine.
[16] D. Leehey,et al. Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[17] A. Kausz,et al. Ferumoxytol for treating iron deficiency anemia in CKD. , 2008, Journal of the American Society of Nephrology : JASN.
[18] A. Pai,et al. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose , 2011, BioMetals.
[19] R. Zager,et al. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. , 2010, American journal of physiology. Renal physiology.
[20] J. Toblli,et al. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] P. Kerr,et al. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[22] H. Uno,et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. , 2010, The New England journal of medicine.
[23] J. Coresh,et al. GFR estimation: from physiology to public health. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] R. Agarwal. On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. , 2005, AJP - Renal Physiology.
[25] E. Unger,et al. Erythropoiesis-stimulating agents--time for a reevaluation. , 2010, The New England journal of medicine.
[26] A. Kausz,et al. Iron therapy in the pediatric hemodialysis population , 2004, Pediatric Nephrology.
[27] I. Macdougall,et al. The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] D. V. Van Wyck,et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. , 2005, Kidney international.
[29] A. Mangione,et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[30] P. Sarafidis,et al. Slow Intravenous Iron Administration Does Not Aggravate Oxidative Stress and Inflammatory Biomarkers during Hemodialysis: A Comparative Study between Iron Sucrose and Iron Dextran , 2007, American Journal of Nephrology.